amgen在2027年达到碳中立

千橡木,加利福尼亚州。 1月11日,2021年/ prnewswire / - amgen.(纳斯达克:AMGN)今天宣布推出了一个新的七年环境可持续性计划,其中包括实现碳中立性的承诺,同时还减少了40%和垃圾所处理的水量,减少了75%的废物。

“作为一家用于服务患者的任务的基于科学的公司,我们了解气候变化在全球人类健康方面的深刻影响,” 罗伯特A. Bradway.,Amgen主席和首席执行官。“我们的新承诺扩展了我们以前的成就和驱动器 amgen.继续领导环境可持续性,将有利于我们的患者,员工,股东和社区。“

自2007年以来, amgen.已实施项目导致碳排放减少33%,水量减少30%,浪费减少28%。即使公司提高生产能力,达到了达到了100多个国家,也达到了这些减少,扩大了100多个国家,大大增长了收入。

amgen.将投资超过 2亿美元为了达到这2027个环境承诺,预计此类投资将有助于我们不仅仅是更加环保的可持续性,而且更加灵活,效率更为灵活,导致在同一时期这些效率的运营成本减少。本公司将专注于使用创新技术,从而大大减少碳排放量 amgen.-OWNOWED运营,以及采购可再生能源。例如, amgen.最新的生物化制造厂 新加坡比传统的生物制造设施产生70%的碳。该公司建立了第二种这样的工厂 罗德岛

如果无法从其运营中删除碳排放, amgen.将投资于可持续发展项目,隔离或避免温室气体排放。此外, amgen.将与其供应商聘用,协助和鼓励整个价值链中的碳减少。

更多信息 amgen.环境计划可以找到这里

关于amgen.
AMGEN致力于通过发现,开发,制造和提供创新的人类治疗,解锁患有严重疾病的患者的生物学潜力。这种方法始于使用高级人类遗传学等工具来解开疾病的复杂性并理解人类生物学的基本面。

Amgen专注于高度未满足的医疗需求领域,并利用其专业知识来争取改善健康成果的解决方案,并大大改善人们的生活。自1980年以来的生物技术先驱,AMGEN已经发展成为世界领先的独立生物技术公司之一,已达到全世界数百万患者,正在开发一种具有突出潜力的药物管道。

有关更多信息,请访问www.dress-whsle.com.并关注我们www.twitter.com/amgen.

前瞻性陈述
此新闻稿包含基于当前预期和Amgen的信仰的前瞻性陈述。除了历史事实陈述之外的所有陈述是可能被视为前瞻性陈述的陈述,包括任何关于合作,或潜在合作的任何陈述,或潜在合作,包括适应性生物技术(包括关于有关的陈述这种协作的能力发现和开发靶向SARS-COV-2的全人中和抗体,以潜在预防或治疗Covid-19),Beigene,Ltd。或蛋白蛋白收购,包括预期的OttZLA销售增长和非GAAP的时机EPS ACCRETION,以及收入,运营利润率,资本支出,现金,其他金融指标,预期的法律,仲裁,政治,监管或临床结果或做法,客户和处方者模式或做法,报销活动和结果,效果Pandemics或其他广泛的健康问题,如正在进行的Covid-19关于我们业务的大流行,结果与OcTezla的研究作为Covid-19的潜在治疗以及其他此类估计和结果有关的进展或效果。前瞻性陈述涉及显着的风险和不确定性,包括以下讨论的风险和不确定性,并在AMGE提出的证券和交换委员会报告中更全面地描述,包括我们最近关于表格10-K的年度报告和表格10-Q的任何后期报告和关于表格8-k的报告。除非另有说明,否则A​​MGEN正在向本新闻发布的日期提供此信息,并且不会因新信息,未来事件或其他方式而履行本文件中包含的任何前瞻性陈述的任何义务。

无法保证前瞻性陈述,实际结果可能与我们项目的实际结果不同。我们的成果可能受到在国内和国际上成功市场的能力的影响,涉及当前和未来产品的临床和监管开发,最近推出的产品的销售增长,其他产品的竞争,包括生物仿制物,困难或制造业的延误产品和全球经济条件。此外,我们的产品的销售受到第三方付款人的定价,政治和公共审查和报销政策的影响,包括政府,私人保险计划和管理护理提供者,可能受到监管,临床和准则发展和国内的影响和托管护理和医疗费用遏制的国际趋势。此外,我们的研究,测试,定价,营销和其他业务受到国内外政府监管机构的广泛监管。在市场上,我们或其他人可以识别我们的产品,包括我们的设备的安全性,副作用或制造问题。我们的业务可能受到政府调查,诉讼和产品责任索赔的影响。此外,我们的业务可能会受到新税务立法或接触额外税收负债的影响。如果我们未能达到美国与美国政府之间的企业诚信协定的合规义务,我们可能会受到重大制裁。 Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

联系人:amgen,千橡木
梅根·福克斯,805-447-1423(媒体)
Trish Rowland,805-447-5631(媒体)
arvind sood,805-447-1060(投资max万博客户端苹果者)

amgen标志。(prnewsfoto / amgen)(prnewsfoto /)

cisision.查看原始内容以下载多媒体:http://www.prnewswire.com/news-releases/amgen-to-achieve-carbon-neutrality-by-2027-301205666.html.

资源 amgen.